J.Safra Asset Management Corp Buys 736 Shares of Vaxcyte, Inc. (NASDAQ:PCVX)

J.Safra Asset Management Corp lifted its stake in shares of Vaxcyte, Inc. (NASDAQ:PCVX) by 62.9% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,907 shares of the company’s stock after acquiring an additional 736 shares during the period. J.Safra Asset Management Corp’s holdings in Vaxcyte were worth $156,000 at the end of the most recent quarter.

Several other large investors also recently made changes to their positions in the stock. Nisa Investment Advisors LLC increased its position in shares of Vaxcyte by 5.2% during the third quarter. Nisa Investment Advisors LLC now owns 2,209 shares of the company’s stock worth $252,000 after acquiring an additional 110 shares in the last quarter. CIBC Asset Management Inc increased its position in shares of Vaxcyte by 3.6% during the third quarter. CIBC Asset Management Inc now owns 3,136 shares of the company’s stock worth $358,000 after acquiring an additional 110 shares in the last quarter. Smartleaf Asset Management LLC increased its position in shares of Vaxcyte by 188.4% during the fourth quarter. Smartleaf Asset Management LLC now owns 398 shares of the company’s stock worth $33,000 after acquiring an additional 260 shares in the last quarter. KBC Group NV increased its position in shares of Vaxcyte by 13.6% during the third quarter. KBC Group NV now owns 2,683 shares of the company’s stock worth $307,000 after acquiring an additional 322 shares in the last quarter. Finally, Amalgamated Bank increased its position in shares of Vaxcyte by 8.6% during the third quarter. Amalgamated Bank now owns 4,081 shares of the company’s stock worth $466,000 after acquiring an additional 322 shares in the last quarter. Institutional investors own 96.78% of the company’s stock.

Vaxcyte Price Performance

Shares of PCVX stock opened at $73.89 on Thursday. The stock has a market cap of $9.51 billion, a P/E ratio of -16.06 and a beta of 1.02. The company has a fifty day moving average price of $83.74 and a two-hundred day moving average price of $94.70. Vaxcyte, Inc. has a one year low of $58.10 and a one year high of $121.06.

Vaxcyte (NASDAQ:PCVX) last announced its quarterly earnings results on Tuesday, February 25th. The company reported ($1.02) EPS for the quarter, beating analysts’ consensus estimates of ($1.16) by $0.14. As a group, equities research analysts anticipate that Vaxcyte, Inc. will post -4.21 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research analysts recently weighed in on PCVX shares. Needham & Company LLC reaffirmed a “buy” rating and issued a $140.00 target price on shares of Vaxcyte in a research report on Wednesday, February 26th. The Goldman Sachs Group started coverage on shares of Vaxcyte in a research report on Friday, December 20th. They issued a “buy” rating and a $135.00 target price for the company. Guggenheim reaffirmed a “buy” rating and issued a $160.00 target price on shares of Vaxcyte in a research report on Wednesday, February 26th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Vaxcyte in a research report on Wednesday, November 6th. Nine analysts have rated the stock with a buy rating, Based on data from MarketBeat, Vaxcyte currently has an average rating of “Buy” and a consensus price target of $147.50.

Insider Buying and Selling at Vaxcyte

In other news, CFO Andrew Guggenhime sold 8,000 shares of the firm’s stock in a transaction dated Wednesday, December 18th. The shares were sold at an average price of $88.78, for a total transaction of $710,240.00. Following the completion of the sale, the chief financial officer now owns 109,491 shares in the company, valued at approximately $9,720,610.98. This trade represents a 6.81 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Grant Pickering sold 2,366 shares of the firm’s stock in a transaction dated Monday, December 9th. The stock was sold at an average price of $92.25, for a total transaction of $218,263.50. Following the sale, the chief executive officer now owns 136,215 shares of the company’s stock, valued at approximately $12,565,833.75. This represents a 1.71 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 56,616 shares of company stock worth $4,768,521 over the last quarter. 3.10% of the stock is currently owned by insiders.

About Vaxcyte

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.